Patents Issued in January 19, 2017
-
Publication number: 20170015718Abstract: The invention relates to pro-apoptotic peptides, useful in cancer treatment, and to chimeric peptides comprising a cell penetrating peptide linked to a pro-apoptotic peptide, wherein the pro-apoptotic peptide binds Ras or Raf proteins.Type: ApplicationFiled: July 3, 2014Publication date: January 19, 2017Inventors: ANGELITA REBOLLO GARCIA, FARIBA NEMATI, DIDIER DECAUDIN
-
Publication number: 20170015719Abstract: The invention pertains to methods for using chimeric polypeptides of the formula: B-X wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B-X are also included.Type: ApplicationFiled: July 26, 2013Publication date: January 19, 2017Applicants: Inserm, Centre National de la Recherche Scientifique (CNRS), Institut Curie, Universite Pierre Et Marie Curie (Paris 6)Inventors: Bruno Goud, Ludger Johannes
-
Publication number: 20170015720Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.Type: ApplicationFiled: March 30, 2015Publication date: January 19, 2017Applicants: Biontech Cell & Gene thrapies GMBH, Tron - Translationale Onkologie Ander Universitata tsmedizin Der Johannes Gutenberg-Universitat Main, Univeritatsmedizin der Johannes Gutenberg-, Ganymed Pharmceuticals AGInventors: Ugur SAHIN, Özlem TÜRECI, Petra SIMON, Tana OMOKOKO, Holger HOFF, Ralf-Holger VOSS, Andrea BREITKREUZ, Kathleen HOBOHM, Karolina, Anna , MROZ
-
Publication number: 20170015721Abstract: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.Type: ApplicationFiled: September 30, 2016Publication date: January 19, 2017Inventor: James W. LILLARD, JR.
-
Publication number: 20170015722Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.Type: ApplicationFiled: July 22, 2016Publication date: January 19, 2017Applicant: The Board of Trustees of the Leland Stanford Junior University, Office of the General CounselInventors: Kenan Christopher GARCIA, Aron Levin, Aaron Ring
-
Publication number: 20170015723Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology in described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon like alpha 2b (HuIFN-?2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.Type: ApplicationFiled: January 11, 2016Publication date: January 19, 2017Inventors: Haitao Wang, Chunsheng Mao, Jizhi Li, Ling Wang, Yong Du, Longbin Liu, Jing Xu, Rui Zhang
-
Publication number: 20170015724Abstract: We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists.Type: ApplicationFiled: October 2, 2016Publication date: January 19, 2017Applicant: ASTERION LIMITEDInventors: Peter ARTYMIUK, Ian WILKINSON, Richard ROSS
-
Publication number: 20170015725Abstract: A process is described for purifying insulin and insulin analogs that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed in the presence of a water miscible organic modifier and at an elevated temperature followed by reverse phase chromatography performed in the presence of a water miscible organic modifier and at an elevated temperature.Type: ApplicationFiled: March 11, 2015Publication date: January 19, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Allison D. Ortigosa, Michael P. Coleman, Shibu T. George, Michael A. Rauscher, Mark C. Sleevi, Kartoa Chow
-
Publication number: 20170015726Abstract: The present invention relates to compositions, methods and kits for delivery of active agents (X) to cells or tissues that express proteoglycans. More specifically, the present invention relates to conjugates comprising (HB-linker)n-Xm-(linker-HB)o, where HB is a heparin binding protein, X is an active agent such as a therapeutic protein (including a functional fragment or variant thereof), or a therapeutic small molecule, linker is a linker entity and m is an integer of at least 1, and n+o is an integer of at least 1. Other aspects relate to use of a HB-X conjugate in methods to deliver active agents to cartilage for the treatment of cartilage related disease and disorders, the use of the HB-X conjugate in methods to deliver active agents to neuronal tissues (e.g., brain and spinal cord) for the treatment of neurological disorders, and the use of the HB-X conjugates in methods for the treatment of eye conditions and disorders and inflammatory conditions and disorders.Type: ApplicationFiled: August 2, 2016Publication date: January 19, 2017Inventors: Richard T. Lee, Parth Patwari, Francesco Loffredo, James Pancoast
-
Publication number: 20170015727Abstract: The present invention provides a method for engineering a T-cell receptor domain polypeptide comprising at least one modification in a structural loop region of the T-cell receptor domain polypeptide and determining the binding of the T-cell receptor domain polypeptide to an epitope of an antigen, wherein the unmodified T-cell receptor domain polypeptide does not significantly bind to the epitope. The present invention also covers modified T cell receptor domain polypeptides, their use and libraries containing the modified T cell receptor domain polypeptides.Type: ApplicationFiled: October 3, 2016Publication date: January 19, 2017Inventors: Gottfried Himmler, Florian Rüker
-
Publication number: 20170015728Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel nuclear receptors comprising a substitution mutation and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene within a host cell using this inducible gene expression system.Type: ApplicationFiled: December 17, 2015Publication date: January 19, 2017Applicant: Intrexon CorporationInventors: Subba Reddy PALLI, Marianna Zinovievna Kapitskaya
-
Publication number: 20170015729Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules fused to a polypeptide such as e.g. an antibody binding protein or a Fc domain.Type: ApplicationFiled: October 4, 2016Publication date: January 19, 2017Applicant: Novo Nordisk A/SInventors: Gert Bolt, Kristian Kjaergaard, Peder Lisby Noerby, Ole Hvilsted Olsen
-
Publication number: 20170015730Abstract: Disclosed are compositions and methods for accelerating wound closure and preventing inhibiting or reducing scarring or fibrosis. The methods of the present invention include administering to a person in need thereof an effective amount of a pharmaceutical composition comprising collagen 7 and/or one or more functional fragments or variants thereof. The functional fragments generally comprise at least one of the nine Fibronectin Type III-like Region of the NC1 region of collagen 7.Type: ApplicationFiled: April 8, 2015Publication date: January 19, 2017Applicant: University of Southern CaliforniaInventors: Mei CHEN, David T. WOODLEY
-
Publication number: 20170015731Abstract: Embodiments of the present invention illustrate methods of preventing transplantation rejection. In certain embodiments, a subject in need of an organ or non-organ transplantation can be pretreated with an AAT composition to reduce the incidence of transplantation rejection in the subject. Other embodiments include treating a subject with a composition including AAT before, during or after plastic surgery.Type: ApplicationFiled: September 28, 2016Publication date: January 19, 2017Inventors: Peter Gottlieb, Charles Dinarello
-
Publication number: 20170015732Abstract: The present invention relates to a method for purifying an immunoglobulin, and more particularly, to a method for purifying an immunoglobulin, which comprises: dissolving immunoglobulin-containing plasma protein fraction I+II+III or fraction II+III; adding caprylate to the solution to cause precipitation; performing dialysis and concentration after removal of the precipitate; performing anion exchange resin and ceramic cation exchange resin purification processes to effectively remove a solvent and detergent added to inactivate viruses; and performing elution while maintaining salt concentration at a constant level to maintain the immunoglobulin polymer content at a low level.Type: ApplicationFiled: March 11, 2014Publication date: January 19, 2017Applicant: GREEN CROSS HOLDINGS CORPORATIONInventors: Dong-Hwarn Park, Ki-Hwan Son, Kang Yun Seo, Sung Min Choi, Gun Sul Lee, Ki-Yong Kim
-
Publication number: 20170015733Abstract: The invention relates to binding molecules against Chikungunya virus, which are able of neutralizing Chikungunya virus infectivity, and which can be used with therapeutic, diagnosis or research purposes, as well as to a pharmaceutical composition comprising said binding molecules.Type: ApplicationFiled: July 29, 2016Publication date: January 19, 2017Inventors: Lucile Warter, Jean-Pierre Abastado, Alessandra Nardin, Cheng-I Wang
-
Publication number: 20170015734Abstract: Antibodies having Fab regions that specifically bind to Staphylococcus aureus protein A are capable of mediating opsinization of Staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein A. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing Staphylococcus aureus infections.Type: ApplicationFiled: September 30, 2016Publication date: January 19, 2017Inventor: John Simard
-
Publication number: 20170015735Abstract: The present invention is directed to a monoclonal antibody that binds specifically to a Staphylococcus aureus glucosaminidase and inhibits in vivo growth of S. aureus. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating S. aureus infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.Type: ApplicationFiled: October 3, 2016Publication date: January 19, 2017Inventors: Edward M. SCHWARZ, Mark A. SULLIVAN, John L. DAISS
-
Publication number: 20170015736Abstract: The present invention relates to antibodies that bind to a polypeptide at an epitope in the amino acid sequence of SEQ ID NO: 1 (e.g., a sericin polypeptide). The invention also provides methods and kits using the antibodies of the invention. In some embodiments, the antibody binds to a polypeptide at an epitope in the amino add sequence of SEQ ID NO: 2. In some embodiments, the antibody binds to a polypeptide at an epitope in the amino add sequence of SEQ ID NO: 3. In some embodiments, the polypeptide is a sericin polypeptide (e.g., a sericin isoform 1B polypeptide). In a related aspect, the invention features a method for selectively detecting sericin in a sample.Type: ApplicationFiled: March 12, 2015Publication date: January 19, 2017Applicant: Cerapedics, Inc.Inventors: James J. BENEDICT, Tristan Stuart BARNES, Claude George LERNER
-
Publication number: 20170015737Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.Type: ApplicationFiled: July 2, 2016Publication date: January 19, 2017Inventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
-
Publication number: 20170015738Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.Type: ApplicationFiled: July 12, 2016Publication date: January 19, 2017Applicant: H. Lundbeck A/SInventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist
-
Publication number: 20170015739Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.Type: ApplicationFiled: July 12, 2016Publication date: January 19, 2017Applicant: H. Lundbeck A/SInventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
-
Publication number: 20170015740Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.Type: ApplicationFiled: September 30, 2016Publication date: January 19, 2017Inventors: Russell P. Rother, Camille BEDROSIAN, Stephen P. SQUINTO, Leonard BELL
-
Publication number: 20170015741Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.Type: ApplicationFiled: October 3, 2016Publication date: January 19, 2017Inventors: Leonard BELL, Russell P. ROTHER
-
Publication number: 20170015742Abstract: Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.Type: ApplicationFiled: June 15, 2016Publication date: January 19, 2017Inventors: Jijie GU, Diana BOWLEY, Lucia EATON, Feng DONG, Lorenzo BENATUIL, Tariq GHAYUR, Ravi CHARI, Matthew RIESER, Anca CLABBERS
-
Publication number: 20170015743Abstract: The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies.Type: ApplicationFiled: August 4, 2016Publication date: January 19, 2017Inventors: Daniel T. Mytych, Narendra Chirmule, Dohan K. Weeraratne
-
Publication number: 20170015744Abstract: The present invention provides an anti-blood coagulant capable of selectively suppressing a pathological blood coagulation reaction without increasing the risk of major bleeding. The anti-blood coagulant in accordance with the present invention includes a binding inhibiting component that inhibits the binding of LOX-1 to at least one of factor V and factor Va.Type: ApplicationFiled: December 23, 2014Publication date: January 19, 2017Inventors: Tatsuya SAWAMURA, Yoshiko FUJITA, Akemi KAKINO
-
Publication number: 20170015745Abstract: Methods and compositions are disclosed to engineer chloroplast comprising heterologous genes encoding target binding domain fused to a eukaryotic toxin and produced within a subcellular organelle, such as a chloroplast. The present disclosure demonstrates that when chloroplasts are used, toxins normally refractive to production in eukaryotic cells may be used to produce recombinant fusion proteins with binding domains that are soluble, properly folded and post-translationally modified, where the multifunctional activity of the fusion protein is intact. The binding domains may include those from antibodies, receptors, hormones, cytokines, chemokines, and interferons. The present disclosure also demonstrates the utility of plants, including green algae, for the production of complex multi-domain proteins as soluble bioactive therapeutic agents.Type: ApplicationFiled: July 5, 2016Publication date: January 19, 2017Inventors: Stephen P. Mayfield, Miller Tran
-
Publication number: 20170015746Abstract: Aspects of the invention described herein, concern approaches to make genetically modified T-cells comprising a chimeric antigen receptor for human therapy. In some alternatives, the methods utilize a selection and/or isolation of CD4+ and/or CD8+ T-cells from a mixed T-cell population, such as, peripheral blood or apheresis derived mononuclear cells. Once selected/isolated, the CD4+ and/or CD8+ T-cells are then activated, genetically modified, and propagated, preferably, in separate or isolated cultures in the presence of one or more cytokines, which support survival, engraftment and/or proliferation of the cells, as well as, preferably promoting or inducing the retention of cell surface receptors, such as CD62L, CD28, and/or CD27.Type: ApplicationFiled: April 8, 2015Publication date: January 19, 2017Applicant: Seattle Children's Hospital (Dba Seattle Children's Research Institute)Inventor: Michael C. Jensen
-
Publication number: 20170015747Abstract: This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.Type: ApplicationFiled: September 30, 2016Publication date: January 19, 2017Inventors: Peter Armstrong Thompson, Peter Robert Baum, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan
-
Publication number: 20170015748Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF 1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF 1R polypeptide. Humanized forms of the camelid VHH are also generated.Type: ApplicationFiled: December 4, 2014Publication date: January 19, 2017Applicant: National Research Council of CanadaInventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
-
Publication number: 20170015749Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Daltons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF1R polypeptide. Humanized forms of the camelid VHH are also generated.Type: ApplicationFiled: December 4, 2014Publication date: January 19, 2017Applicant: National Research Council of CanadaInventors: Danica Stanimirovic, Kristin Kemmerich, Arsalan S. Haqqani, Traian Sulea, Mehdi Arbabi-Ghahroudi, Bernard Massie, Rénald Gilbert
-
Publication number: 20170015750Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.Type: ApplicationFiled: September 29, 2016Publication date: January 19, 2017Applicant: AMGEN INC.Inventors: Shaw-Fen Sylvia HU, Ian Nevin FOLTZ, Chadwick Terence KING, Yang LI, Taruna Arora
-
Publication number: 20170015751Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIA and uses for same.Type: ApplicationFiled: September 30, 2016Publication date: January 19, 2017Inventors: Jasbir Seehra, Erik Martinez-Hackert
-
Publication number: 20170015752Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: October 4, 2016Publication date: January 19, 2017Applicant: HOFFMANN-LA ROCHE INC.Inventors: Georg FERTIG, Alexander FIDLER, Klaus KALUZA, Marlene THOMAS, Carola RIES, Stefan SEEBER
-
Publication number: 20170015753Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.Type: ApplicationFiled: July 18, 2016Publication date: January 19, 2017Inventors: John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
-
Publication number: 20170015754Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: ApplicationFiled: September 8, 2016Publication date: January 19, 2017Inventors: Anish SURI, Steven SHERIFF, Suzanne SUCHARD, Aaron YAMNIUK, Stanley KRYSTEK, James TAMURA, James BRYSON, Steven GRANT, Philip DREW
-
Publication number: 20170015755Abstract: The invention provides compositions and methods for treating cancers. The method comprises administering an anti-angiogenesis agent and an OX40 binding agonist.Type: ApplicationFiled: September 29, 2016Publication date: January 19, 2017Applicant: Genentech, Inc.Inventors: Kevin WALSH, Patricia DE ALMEIDA, Changchun DU, Jeong KIM, Jing ZHU, Jack BEVERS, III, James ANDYA, Ye SHEN
-
Publication number: 20170015756Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa (sLea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.Type: ApplicationFiled: September 23, 2016Publication date: January 19, 2017Inventors: Ritsuko SAWADA, Shu-Man SUN, Wolfgang SCHOLZ
-
Publication number: 20170015757Abstract: Embodiments described herein provide anti-fibulin-3 antibodies, recombinant proteins that bind specifically to fibulin-3, compositions and the treatment methods comprising these antibodies and recombinant proteins.Type: ApplicationFiled: March 10, 2015Publication date: January 19, 2017Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Mariano S. Viapiano, Nandhu Mohan Sobhana, Ennio Antonio Chiocca
-
Publication number: 20170015758Abstract: Provided herein are methods of modulating and redirecting an immune response. Compositions and methods for killing targeted cells in a cell population are also provided wherein, a cell population containing target cells expressing a target associated antigen and T cells are contacted with 1, 2, or more immune checkpoint antagonists and a multispecific T cell-redirecting agent that specifically binds the target associated antigen expressed on the target cells and specifically binds a T cell surface antigen.Type: ApplicationFiled: January 21, 2015Publication date: January 19, 2017Inventors: Scott A. HAMMOND, Michael A. MORSE, Takuya OSADA, Herbert Kim LYERLY
-
Publication number: 20170015759Abstract: The invention relates to conjugates of hyaluronic acid oligomer according to the general formulae I, II III or IV, or a salt thereof, the method of preparation thereof and use thereof, where the oligomer is bonded to the respective substrate by its ending anomeric center via a bi-functional amino linker by means of an amino or imino bond. This type of conjugates allows releasing oligomers in their native form. The prepared systems exhibited an enhanced biological activity against selected lines of cancer cells.Type: ApplicationFiled: March 10, 2015Publication date: January 19, 2017Inventors: Radovan Buffa, Ivana Basarabova, Kristina Nesporova, Tereza Ehlova, Ondrej Kotland, Petra Sedova, Leos Hromek, Vladimir Velebny
-
Publication number: 20170015760Abstract: A method for preparing a functionalized polymer, the method comprising the steps of preparing a reactive polymer and reacting the reactive polymer with a heterocyclic nitrile compound.Type: ApplicationFiled: September 28, 2016Publication date: January 19, 2017Applicant: BRIDGESTONE CORPORATIONInventors: Steven Luo, Ryouji Tanaka, Kouichirou Tani
-
Publication number: 20170015761Abstract: Disclosed are a modified conjugated diene-based polymer represented by specific Chemical Formula, a method of preparing the same, and a rubber composition including the same.Type: ApplicationFiled: December 11, 2015Publication date: January 19, 2017Applicant: LG Chem, Ltd.Inventors: He-Seung LEE, No-Ma KIM, Hae-Sung SOHN
-
Publication number: 20170015762Abstract: A process of polymerization of a vinylic monomer uses a polymerization regulator/initiator that is a compound represented by Formula I.Type: ApplicationFiled: March 4, 2015Publication date: January 19, 2017Inventors: Jon Debling, Peter Nesvadba, Klaus-Dieter Hungenberg
-
Publication number: 20170015763Abstract: Disclosed are an anionic polymerization initiator, which is a reaction product of an organometallic compound and a compound including an alkyl chain having a tertiary amino functional group, and a method of preparing a conjugated diene-based copolymer using the same.Type: ApplicationFiled: October 14, 2015Publication date: January 19, 2017Applicant: LG Chem, Ltd.Inventors: Dae-June Joe, Min-Soo Kim, Won-Mun Choi
-
Publication number: 20170015764Abstract: A method comprising a) calcining a silica support at temperature in the range of from about 100° C. to about 500° C. to form a precalcined silica support; b) contacting the precalcined silica support with a titanium alkoxide to form a titanated support; c) subsequent to b), contacting the titanated support with a polyol to form a polyol associated titanated support (PATS); d) contacting at least one of the silica support, pre-calcined silica support, the titanated support, the PATS, or combinations thereof with a chromium-containing compound to form a polymerization catalyst precursor; e) drying the polymerization catalyst precursor to form a dried polymerization catalyst precursor; and f) calcining the dried polymerization catalyst precursor to produce a polymerization catalyst, wherein less than about 0.1 wt. % of a highly reactive volatile organic compound (HRVOC) is emitted during the calcining of the dried polymerization catalyst precursor.Type: ApplicationFiled: September 30, 2016Publication date: January 19, 2017Inventors: Jeremy M. Praetorius, Eric D. Schwerdtfeger, Max P. McDaniel, Ted H. Cymbaluk, Connor D. Boxell, Kathy S. Collins, Alan L. Solenberger
-
Publication number: 20170015765Abstract: It is an object of the present invention to provide a cyanine-based coloring composition having higher heat resistance, as compared with a conventional coloring composition. The present invention relates to a compound represented by the following general formula (1), a polymer having a monomer unit derived from the compound, along with a coloring composition, a coloring composition for a color filter, and a colored resin comprising the above-described compound or the above-described polymer.Type: ApplicationFiled: March 5, 2015Publication date: January 19, 2017Applicant: Wako Pure Chemical Industries, Ltd.Inventors: Yukihiko SHIDA, Katsufumi SUZUKI, Tomoaki HORIE
-
Publication number: 20170015766Abstract: The present invention provides a polybutadiene having improved workability and abrasion resistance. A polybutadiene according to the present invention has: (A) a Mooney viscosity (ML1+4,100° C.) being 43 or more; (B) a ratio (Tcp/ML1+4,100° C.) of 5 wt % toluene solution viscosity (Tcp) to Mooney viscosity (ML1+4,100° C.) being 0.9 to 2.3; (C) a stress relaxation time (T80) being 10.0 to 40.0 seconds, which is a time until a torque is attenuated by 80% when the torque at the end of ML1+4,100° C.measurement is 100%; and (D) a molecular weight distribution (Mw/Mn) being 2.50 to 4.00.Type: ApplicationFiled: February 19, 2015Publication date: January 19, 2017Applicant: UBE INDUSTRIES, LTD.Inventors: Mitsuharu AMBE, Yuuto KANOU, Takeshi SHODA
-
Publication number: 20170015767Abstract: This invention relates to novel bridged a hafnium transition metal metallocene catalyst compounds having two indenyl ligands substituted at the 4 position, preferably 4 and 7 positions, with a C1 to C10 alkyl, where the 2 and 3 positions are hydrogen (assuming the bridge position is counted as the one position) and the bridging atom is carbon or silicon which is incorporated into a cyclic group comprising 3, 4, 5, or 6 silicon and/or carbon atoms that make up the cyclic ring.Type: ApplicationFiled: September 28, 2016Publication date: January 19, 2017Inventors: Jo Ann M. Canich, Peijun Jiang